Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.43 |
| ▸ | NPC1 | O15118 | 7/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | CPT1A | P50416 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | CLK1 | P49759 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10215326 | 0.91 | RAB9A (0.42) | RAB9ANPC1KDM4ESMN1; SMN2LMNA | |
| SCHEMBL10215331 | 0.90 | NPC1 (0.43) | RAB9ANPC1KDM4ESMN1; SMN2LMNA | |
| SCHEMBL10215288 | 0.90 | RAB9A (0.42) | RAB9ANPC1KDM4ESMN1; SMN2LMNA | |
| SCHEMBL10216317 | 0.89 | RAB9A (0.52) | RAB9ANPC1KDM4ESMN1; SMN2LMNA | |
| SCHEMBL10215329 | 0.88 | HSD17B10 (0.47) | RAB9ANPC1KDM4ESMN1; SMN2LMNA | |
| SCHEMBL10216326 | 0.86 | LMNA (0.40) | RAB9ANPC1KDM4ESMN1; SMN2LMNA | |
| SCHEMBL10215325 | 0.85 | SCD (0.40) | HIF1AMAOB | |
| SCHEMBL10216316 | 0.84 | ROCK2 (0.44) | RAB9ANPC1KDM4ESMN1; SMN2LMNA | |
| SCHEMBL13788157 | 0.80 | EGLN1 (0.46) | RAB9ANPC1SMN1; SMN2LMNAMEN1 | |
| SCHEMBL10215373 | 0.79 | RAB9A (0.51) | RAB9ANPC1KDM4ESMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120053148-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053148-A1 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2011156610-A2 | INHIBITORS OF HEPATITIS C VIRUS | GILEAD SCIENCES, INC. (US) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053148-A1 | INHIBITORS OF HEPATITIS C VIRUS | HAVCR2, FABP1, EIF2AK2 | RAB9A 2221/4885NPC1 50/4885KDM4E 4201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.